scispace - formally typeset
D

Donghoon Choi

Researcher at Yonsei University

Publications -  1107
Citations -  20602

Donghoon Choi is an academic researcher from Yonsei University. The author has contributed to research in topics: Stent & Myocardial infarction. The author has an hindex of 56, co-authored 1015 publications receiving 17538 citations. Previous affiliations of Donghoon Choi include Korea Institute of Science and Technology & Cardiovascular Institute Hospital.

Papers
More filters
Journal ArticleDOI

A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis

TL;DR: Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents.
Journal ArticleDOI

Effect of intravascular ultrasound-guided vs angiography- guided everolimus-eluting stent implantation: The IVUS-XPL randomized clinical trial

TL;DR: The use of IVUS-guided everolimus-eluting stent implantation, compared with angiography-guided stent implants, resulted in a significantly lower rate of the composite of major adverse cardiac events at 1 year, primarily due to lower risk of target lesion revascularization.
Journal ArticleDOI

2,5-Bis(2-octyldodecyl)pyrrolo[3,4-c]pyrrole-1,4-(2H,5H)-dione-based donor-acceptor alternating copolymer bearing 5,5'-di(thiophen-2-yl)-2,2'-biselenophene exhibiting 1.5 cm2·V(-1)·s(-1) hole mobility in thin-film transistors.

TL;DR: A novel diketopyrrolopyrrole-based π-conjugated copolymers P(DPP-alt-DTBSe), 5, and a known copolymer P( DPP-Alt-QT), 4, have been synthesized in 80-90% yield using the Stille coupling reaction.
Journal ArticleDOI

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.

TL;DR: Among patients with acute coronary syndromes treated with drug-eluting stents, ticagrelor monotherapy after 3 months of dual antiplatelet therapy, compared with ticagerelor-based 12-month dual anti Platelet therapy resulted in a modest but statistically significant reduction in a composite outcome of major bleeding and cardiovascular events at 1 year.